Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Stakes Claim In Ovarian Cancer; Other Ovarian Updates At ESMO Are Mixed

Executive Summary

Roche is gearing up for a planned year-end submission of Avastin in advanced ovarian cancer in the EU after making a splash at the European Society for Medical Oncology meeting with updated data from its Phase III ICON7 study showing a progression-free survival benefit.

You may also be interested in...



Ovarian Cancer: Roche's Avastin And Others Show Potential, But Also Raise The "Value" Question

Roche/Genentech rolled out yet more data on Avastin (bevacizumab) in ovarian cancer at the American Society of Clinical Oncology meeting in Chicago June 3-7, but other companies also had promising results for new therapies that might help break the historical 24-month survival barrier for the difficult cancer.

Ovarian Cancer: Roche's Avastin And Others Show Potential, But Also Raise The "Value" Question

Roche/Genentech rolled out yet more data on Avastin (bevacizumab) in ovarian cancer at the American Society of Clinical Oncology meeting in Chicago June 3-7, but other companies also had promising results for new therapies that might help break the historical 24-month survival barrier for the difficult cancer.

Roche's Diagnostic Foothold Gives Genentech A Leg Up In Oncology

Research to be presented at American Society of Clinical Oncology meeting shows role of biomarkers for lead compounds, including vemurafenib, MetMAb and Tarceva.

Related Content

Topics

UsernamePublicRestriction

Register

PS052713

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel